Full-Time

Sales Consultant

Early Intervention, Orthopaedics

Posted on 8/17/2026

Deadline 8/28/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$69k - $110.4k/yr

+ Long-term incentive program

Cleveland, OH, USA

In Person

Field-based role requiring travel to all accounts in the assigned territory, with possible weekend work and limited overnight travel.

Bachelor's, Associate's

Category
Sales & Account Management (1)
Required Skills
Market Research
Sales
Inventory Management
CRM
Data Analysis

Get referred to Johnson & Johnson

See people who can refer or advise you

Requirements
  • A bachelor's degree and at least two years of sales or professional experience, preferably within pharmaceutical, biotechnology, or medical industries, or an associate degree and at least four years of sales or professional experience, preferably within those industries.
  • Residence in or ability to relocate to the posted territory.
  • Willingness and ability to travel to all accounts within the assigned territory, including possible weekend work and limited overnight travel.
  • A valid driver's license issued in the United States.
  • Strong negotiation and strategic selling capabilities with a track record of success.
  • Clinical excellence, business sense, and knowledge of and ability to navigate the healthcare ecosystem.
  • Strong problem-solving skills and experience in data analysis.
  • Results orientation, efficient organization, attention to detail, and a sense of urgency.
  • Strong written and oral interpersonal communication.
  • Ability to work independently and autonomously as well as with a team.
  • Self-motivation and a proactive, positive approach.
Responsibilities
  • Sell and manage the Monovisc, Orthovisc, and PEAK PRP product lines in clinical settings within an assigned territory.
  • Develop and implement a business plan to improve growth within the Early Intervention product platform.
  • Work with surgeons, office staff, administration, pain management specialists, and rheumatologists throughout the product sales cycle.
  • Act as an expert in viscosupplementation and other minimally invasive treatment modalities.
  • Identify and qualify prospective accounts.
  • Develop and implement account-specific plans and selling strategies to grow sales and convert new business using tools including an online benefits and reimbursement web portal.
  • Achieve business plan objectives by meeting territory quotas and growth objectives.
  • Drive product sales within an assigned territory or set of named accounts.
  • Use product and customer knowledge to present, demonstrate, and ensure proper utilization of products.
  • Actively promote special marketing promotions and support strategic selling objectives.
  • Gain access to appropriate customers and build effective relationships with key surgeons, office staff, administration, pain management specialists, and rheumatologists.
  • Improve patient care and serve customers as a problem solver while maintaining response time and follow-up.
  • Educate surgeons, office staff, and administration through in-services and tools including an online benefits and reimbursement web portal.
  • Maintain sales equipment and promotional materials in proper condition and use them to support territory efforts.
Desired Qualifications
  • At least three years of relevant sales or professional experience, preferably within pharmaceutical, biotechnology, or medical industries.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 sales hit $25.3 billion, and guidance rose to $101.1 billion.
  • Tremfya surged 72.5% to $2 billion, proving the immunology replacement strategy works.
  • August 21, 2026 TECVAYLI-daratumumab approval and MONARCH QUEST 3 clearance expand pipelines.

What critics are saying

  • July 2026 talc settlement needs 95% claimant approval; failure reopens 76,000 claims.
  • Stelara biosimilars keep crushing legacy revenue, and replacement drugs must sustain 2027 growth.
  • MedTech growth lagged Q2 expectations; Intuitive Surgical and Medtronic intensify hospital-buying competition.

What makes Johnson & Johnson unique

  • J&J spans pharmaceuticals, MedTech, and cash-generating scale after Kenvue’s 2023 spinout.
  • Tremfya, Darzalex, Carvykti, and Tecvayli offset Stelara’s 55% Q2 decline.
  • AAA balance sheet and 64-year dividend streak signal resilience through patent cliffs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-2%
Yahoo Finance
Aug 24th, 2026
Pfizer and J&J navigate patent cliffs with newer drugs offsetting blockbuster losses

Pfizer and Johnson & Johnson are navigating patent cliffs as key drugs lose exclusivity, with their latest results showing differing stages of transition. Pfizer's revenue excluding COVID products grew 5% operationally in Q2 2026, with newer medicines like Padcev and Vyndaqel contributing. The company expects $9.7 billion in cost savings through 2029 to support margins during the transition. Johnson & Johnson's Innovative Medicine sales rose 7.8%, despite Stelara revenue declining 55%. Tremfya sales surged 72.5% to $2 billion, helping offset losses alongside growth from oncology and neuroscience products. Johnson & Johnson raised 2026 guidance, with reported sales expected to reach $101.1 billion and adjusted EPS of $11.68. Its MedTech division provides additional diversification that pure pharmaceutical company Pfizer lacks, suggesting Johnson & Johnson's transition is more advanced.

Yahoo Finance
Aug 21st, 2026
J&J's TECVAYLI plus daratumumab approved in Europe for relapsed/refractory multiple myeloma

The European Commission has approved Johnson & Johnson's TECVAYLI (teclistamab) combined with daratumumab for treating adults with relapsed or refractory multiple myeloma who have received at least one prior therapy. The approval, based on Phase 3 data, makes this immunotherapy doublet available as early as second-line treatment. The combination demonstrated statistically significant improvements in progression-free and overall survival versus standard care regimens. The drugs work complementarily, with daratumumab modulating the immune system to enhance T-cell fitness and activation, amplifying teclistamab's ability to kill myeloma cells. Over 90% of patients who were progression-free at six months remained so at three years. The treatment offers an off-the-shelf, steroid-sparing immunotherapy option for patients who often experience shorter remissions with each subsequent therapy line.

Yahoo Finance
Aug 20th, 2026
J&J CEO signals double-digit growth by decade's end on new drug launches

Johnson & Johnson's chief executive says the company has a "line of sight to double-digit growth by the end of the decade", driven by three newer drugs: Icotyde, Inlexzo and Rybrevant. The pharmaceutical company spun off its healthcare division Kenvue in May 2023 to focus on pharmaceuticals and medical technology. The strategy appears to be working: J&J's share price has risen 55.5% over the past year, compared to 20.7% for the S&P 500. Second-quarter 2026 revenue climbed 6.6% year-over-year to $25.3 billion, primarily driven by its pharmaceutical segment. Tremfya, a drug for inflammatory bowel disease and psoriasis, saw sales jump 72.5% to $2 billion, whilst Darzalex reached $4.2 billion in sales.

Yahoo Finance
Aug 19th, 2026
Johnson & Johnson rises 57% in 12 months with near-zero correlation to S&P 500

Johnson & Johnson has gained 4.4% over the past five trading days whilst the S&P 500 slipped 0.5%. The stock is up 57.3% over the trailing twelve months. Over the past five years, JNJ's correlation to the S&P 500 has been just 0.16, meaning it moves largely independently of the broad market. This independence delivered an annualised return of 11.8% at 17.5% volatility, compared to the index's 13.2% at 17.2% volatility. The company's operational sales grew 5.6% in the second quarter of 2026, reaching $25.3 billion, even as STELARA declined 55.7% under biosimilar competition. TREMFYA grew 71% and now leads new-patient starts in both ulcerative colitis and Crohn's disease. Over the past year, on days when the S&P 500 fell, JNJ moved approximately 65% in the opposite direction.

Highly Capitalized
Aug 19th, 2026
J&J leads Delix's $85M Series C with right of first negotiation on neuroplasticity drug

Johnson & Johnson will lead an $85 million Series C for Delix Therapeutics at a $190 million pre-money valuation. The biotech develops non-hallucinogenic drugs to promote neuroplasticity in psychiatric patients. J&J's term sheet includes a right of first negotiation following Phase II data from Delix's lead compound, DLX-001. This positions J&J as first in line for potential acquisition discussions. Delix announced positive Phase II results in October 2025, showing rapid and durable reductions in depressive symptoms. The FDA cleared a Phase II design allowing patients to self-administer the compound at home. J&J brings relevant experience through Spravato, its FDA-approved nasal spray for treatment-resistant depression. Delix's at-home dosing model offers scalability that Spravato lacks. The financing has not yet closed.